Form 8-K

8-K — DataMeds AI, Inc.

Accession: 0001493152-26-038891

Filed: 2026-08-18

Period: 2026-08-17

CIK: 0002030763

SIC: 5122 (WHOLESALE-DRUGS PROPRIETARIES & DRUGGISTS' SUNDRIES)

Item: Results of Operations and Financial Condition

Item: Financial Statements and Exhibits

Documents

8-K — form8-k.htm (Primary)

EX-99.1 (ex99-1.htm)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: form8-k.htm · Sequence: 1

false

0002030763

2026-08-17

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

Washington,

D.C. 20549

FORM

8-K

CURRENT

REPORT

PURSUANT

TO SECTION 13 OR 15(d) OF THE

SECURITIES

EXCHANGE ACT OF 1934

Date

of Report (Date of earliest event reported): August 17, 2026

DATAMEDS

AI, INC.

(Exact

name of registrant as specified in its charter)

Delaware

001-42530

93-3264234

(State

or other jurisdiction

incorporation)

(Commission

File

Number)

(IRS

Employer

Identification

No.)

3000

Bayport Drive

Suite

950

Tampa,

FL 33607

(Address

of principal executive offices, including zip code)

Registrant’s

telephone number, including area code: (844) 203-6092

(Former

name or former address, if changed since last report)

Check

the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under

any of the following provisions:

☐

Written communications pursuant to Rule 425 under the

Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the

Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b)

under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c)

under the Exchange Act (17 CFR 240.13e-4(c))

Securities

registered pursuant to Section 12(b) of the Act:

Title

of each class

Trading

Symbol(s)

Name

of each exchange on which registered

Common Stock, $0.0001 par

value per share

MEDS

The Nasdaq Capital Market

LLC

Indicate

by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405

of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging

growth company ☒

an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying

with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item

2.02. Results of Operations and Financial Condition.

August 17, 2026, DataMEDS AI, Inc. (the “Company”) issued a press release announcing its financial results for the second

quarter ended June 30, 2026, and provided a business update. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K.

The

information disclosed under this Item 2.02, including Exhibit 99.1 hereto, is being furnished and shall not be deemed “filed”

for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference into any registration

statement or other document pursuant to the Securities Act of 1933, as amended, except as expressly set forth in such filing.

Item

9.01 Financial Statements and Exhibits.

(d)

Exhibits.

Exhibit

No.

Description

of Exhibit

99.1

Press Release of DataMEDS AI, Inc. dated August 17, 2026

104

Cover Page Interactive Data File (embedded within the

Inline XBRL document)

-2-

SIGNATURES

Pursuant

to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by

the undersigned hereunto duly authorized.

Date:

August 18, 2026

DATAMEDS

AI, INC.

By:

/s/

Prashant Patel

Prashant

Patel, President

-3-

EX-99.1

Filename: ex99-1.htm · Sequence: 2

Exhibit 99.1

DataMeds

AI Reports Second Quarter 2026 Financials and Provides Business Update

■ Health

Lives Here app launch with NFL Alumni Health expected in September 2026

■ Revenues

grew 14% reaching $1.779M in Q2/26, beating management projections

■ Corporate

name change from Wellgistics Health, Inc. to DataMeds AI, Inc. in July 2026, which led to

stock symbol change from ‘WGRX’ to ‘MEDS’ on NASDAQ Capital Markets

■ $6.5

million new funding in June 2026 provided capital to support corporate turnaround

■ Pending

transaction with Datavault AI, EOS Technology Holdings, Scilex Holdings and HealthBridge

Associates to consolidate patent protected blockchain, biometrics and pharmaceutical-adjunct

products intellectual properties to deliver the “Health Lives Here” consumer

app, in partnership with NFL Alumni Health (NFLAH), to deliver an effective healthcare experience

to patients in rural communities via local independent pharmacies

■ 1:50

reverse split in May 2026 implemented to partially address NASDAQ delisting risk

■ Holders

of 1,533,930 common shares, representing ~49% of shares outstanding, have entered into lock-up

agreements for at least an additional ninety (90) days

■ Dream

Bowl Meme Coin I token distribution Payment Date set as September 9, 2026 with ratio of 50

tokens per common share owned as of end of business August 7, 2026

■ KareRx

joint venture added Electronic Benefits Verification (EBV) and access to 200,000 patient

lives that began to provide material revenue to rebranded Corexa Pharmacy

■ Neuritek

Therapeutics, Inc. pending acquisition was terminated in May 2026

Tampa,

Fla. / August 17, 2026 / DataMeds AI, Inc. (NASDAQ: MEDS) (“DataMeds AI,” “DataMEDS,” or the “Company”),

an integrated healthcare company leveraging its Health IT infrastructure and artificial intelligence platform EinsteinRx™ combined

with blockchain-enabled smart contracts platform PharmacyChain™ to provide integrated solutions for the compliant delivery of healthcare

and monetization of health data by market participants, today reported second quarter 2026 financials and provided a business update.

The Company is expecting to launch the Health Lives Here (HLH) consumer app together with National Football League Alumni Health (NFLAH)

in September 2026, targeting patients on or contemplating taking GLP-1 agonist medications in rural communities through their local independent

pharmacies. The Company recently made available companion medical food Forzet, indicated for the dietary management of muscle associated

with weight loss therapies, through its pharmacy-focused division Corexa Health (dba Corexa Health AI, www.corexahealthai.com).

“Having

been in leadership now for just under three months, I am excited with the significant progress we are making towards the important milestone

of launching the Health Lives Here app together with NFLAH,” said Gerald Commissiong, interim co-CEO of DataMEDS. “As we

move towards this important milestone, we have successfully begun consolidating the key healthcare infrastructure needed to deliver a

workflow for the patient that will result in a seamless patient experience that will allow patients to engage with their healthcare in

a way that was previously not possible. We intend to engage the patient through telemedicine, a consumer app and their local independent

pharmacist who will be educated on the pharmaceutical-adjunct products we provide through our relationship with Tollo Health that are

intended to help mitigate drugs’ side effects and improve their effectiveness at the initial HLH app launch. As previously stated,

we intend to acquire a CLIA lab that will allow us to offer direct-to-consumer testing, adding an additional layer of service for patients

while allowing us to further integrate our customers’ healthcare data into their patient profiles that patients will be able to

‘opt-in’ to be fed into our EinsteinRx artificial intelligence platform to gain unique healthcare insights, including wearables

data correlated with pharmacodynamic drug response. Ultimately we intend to move all of this data onto the blockchain, protected through

our Datavault AI (NASDAQ: DVLT) license that provides us with patent protection on healthcare data tokenization and monetization, allowing

us to provide patients with an opportunity to participate in the revenue generated through the sale of their health data.

-1-

also intend to perfect intended launch of a drone service to deliver medical products, with biometric confirmation of delivery through

QOLPOM patents being acquired from Scilex Holdings (NASDAQ: SCLX) and EOS Technology Holdings. The first medical products drone service

in the United States was recently completed by Cleveland Clinic, although this service does not include biometric confirmation of

who the medications are being delivered to.

Second

Quarter 2026 Corporate Highlights

● Entered

into agreement to expand Datavault AI PharmacyChain™ license to all of commercial healthcare,

acquire QOLPOM patent portfolios in biometric confirmation of drug consumption through wearables

and biometric confirmation of drug delivery recipient via drones, and a acquire a controlling

interest in Tollo Health (together the ‘Datavault Transaction’)

● Raised

$6.5 million in new funding to drive

● Restructured

$14.5 million in pre-existing debt to provide path to preferred equity swap

● Sequentially

grew revenue 14% quarter-over quarter to $1.779 million when comparted with first quarter

financial 2026 results, exceeding management projections

● Completed

1 for 50 reverse stock split

● Entered

into lock-up agreements with holders of 1,533,930 common shares

● Entered

into joint venture with KareRx, providing access to additional hub services that complement

pre- existing offering, including Electronic Benefits Verification (EBV) services for prospective

clients, Corexa Pharmacy and Health Lives Here, and access to 200,000 patient lives

Third

Quarter 2026 Highlights to Date

● Changed

corporate name to DataMeds AI, Inc. and changed stock symbol to ‘MEDS’

● Appointed

Brett Thompson as Chief Technology Officer

● Updated

Datavault Transaction terms for tax optimization

● Pharmacy-focused

division rebranded under Corexa Health umbrella

● Corexa

Pharmacy launches Tollo Health products Tollovid® and Galectovid™

● Interim

co-CEO Gerald Commissiong featured on Fox Business together with NFL Legend Emmitt Smith

to discuss NFLAH support for Health Lives Here

Expected

Remaining Second Half 2026 Milestones

● Launch

of Health Lives Here consumer app targeting GLP-1 users

● Launch

of Medical Food Forzet targeting weight loss patients

● Closing

of Datavault Transaction

-2-

Loss

from Operations:

The

Company recorded a net operating loss of $18.363 million in the quarter ended June 30, 2026, compared with a net operating loss of $6.672

million in the quarter ended June 30, 2025. The increase in net loss was largely due to the expenses associated with the extinguishment

of debt and general and administrative expenses. Net loss per share in the quarter ended June 30, 2026 was $7.13 on 2.574 million weighted

average shares outstanding, compared to the quarter ended June 30, 2025, where the Company delivered a loss of $5.50 per share on 1.235

million weighted average shares outstanding.

This

press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities.

For

more information on DataMeds Ai, Inc., refer to www.datamedsai.com

About

DataMeds AI, Inc.

DataMeds

AI, Inc. (formerly Wellgistics Health) is a leading Health IT company that focuses on the vertical integration of technology, pharmacy,

pharmaceutical-adjacent and telemedicine business units to deliver a better healthcare experience for consumers. Headquartered in Tampa,

Fla., DataMeds AI incorporates the artificial intelligence platform EinsteinRx™ and blockchain-enabled smart contracts platform

PharmacyChain™ into the Health Lives Here mobile application, and its Corexa Health subsidiary provides pharmacy and pharmacy services,

including the distribution of products developed by Tollo Health, LLC.

Forward-Looking

Statements

This

press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking

statements include, without limitation, statements regarding: future events, including DataMeds AI, Inc.’s payment of the Dream

Bowl Tokens and the timing thereof (including that the Board may change the Payment Date) and the Company’s intention to deliver

liquidity and broad distribution of the Dream Bowl Tokens. These statements are based on management’s current expectations and

are not predictions of actual performance.; the Company’s plans to expand into telemedicine and diagnostic laboratory services;

the Company’s proposed transaction with DataVault AI Inc., Scilex Holding Company, EOS Holdings and HealthBridge Advisors; the

satisfaction or waiver of closing conditions applicable to any of the foregoing; the receipt of stockholder approval and any other required

approvals; the Company’s anticipated business strategy, operating plans and growth opportunities; the integration of telemedicine,

pharmacy, laboratory, wearable-device, artificial intelligence, blockchain and data-management technologies; the proposed development,

commercialization and expansion of EinsteinRx AI, PharmacyChain, Health Lives Here and related platforms; the anticipated growth of the

market for Long COVID products and related treatment approaches; the Company’s ability to empower patients to access, manage, control

or monetize health data; the anticipated benefits of the Company’s technology platforms, strategic relationships and business combinations;

the Company’s capitalization, outstanding securities, lock-up arrangements, public float and registration statements; the Company’s

ability to maintain compliance with Nasdaq listing standards; and the Company’s liquidity, capital resources and ability to fund

operations.

Forward-looking

statements speak only as of the date of this press release. The Company undertakes no obligation to update or revise any forward-looking

statements, whether as a result of new information, future events or otherwise, except as required by law.

DataMeds

AI Media Contact

James

Lambert, Vice President

Rubenstein

Public Relations

Phone:

212.805.3024

Email:

jlambert@rubensteinpr.com

DataMeds

AI Investor Contact

Investor

Relations: IR@wellgisticshealth.com

-3-

PART

I—FINANCIAL INFORMATION

Item

1. Financial Statements.

DATAMEDS

AI, INC.

CONSOLIDATED

BALANCE SHEETS

(Unaudited)

June 30,

December 31,

2026

2025

(Unaudited)

ASSETS

Current assets:

Cash and cash equivalents

$ 2,456,373

$ 42,571

Accounts receivable, net

1,174,336

1,137,219

Inventories, net

1,510,123

1,639,426

Due from related party

26,068

Prepaid and other current assets

465,738

Total current assets

5,632,638

2,819,216

Property, plant and equipment, net

173,879

229,376

Capitalized software

2,297,588

1,850,358

Operating lease, right-of-use-assets

719,645

966,893

Goodwill

14,193,923

Other intangible assets, net

9,656,751

10,314,675

Deposits

85,008

Total assets

$ 32,759,432

$ 30,459,449

LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)

Current liabilities:

Accounts payable

$ 12,612,167

$ 11,665,135

Accounts payable, related party

25,500

Accrued expenses and other liabilities

7,003,749

6,407,722

Due to related parties

225,000

Convertible notes payable, net of debt discount

12,101,803

Current portion of debt obligations, net of debt discount

7,104,225

10,887,520

Operating lease liabilities- current portion

566,379

569,251

Total current liabilities

39,413,823

29,780,128

Notes payable

12,600,000

Operating lease liabilities

249,840

527,122

Total liabilities

$ 52,263,663

$ 42,907,250

Commitments and contingencies (Note 14)

Stockholders’ equity (deficit):

Common stock, $0.0001 par value, 500,000,000 shares authorized, 2,847,198 and 2,045,792 shares issued and 2,836,484 and 2,026,150 shares outstanding as of June 30, 2026 and December 31, 2025, respectively

283

203

Additional paid-in capital

117,632,998

98,583,686

Accumulated deficit

(137,137,512 )

(111,031,690 )

Total stockholders’ equity (deficit)

(19,504,231 )

(12,447,801 )

Total liabilities and stockholders’ equity (deficit)

$ 32,759,432

$ 30,459,449

See

the accompanying notes to the unaudited condensed consolidated financial statements

-4-

DATAMEDS

AI, INC.

CONSOLIDATED

STATEMENTS OF OPERATIONS

(Unaudited)

Three Months Ended

Six Months Ended

June 30,

2026

2025

2026

2025

Net revenues

$ 1,779,860

$ 7,790,865

$ 3,339,423

$ 18,654,308

Cost of net revenues

1,597,656

7,285,113

2,986,998

17,455,915

Gross profit

182,204

505,752

352,425

1,198,393

Operating expenses:

General and administrative

7,056,671

4,859,949

11,925,606

36,032,869

Sales and marketing

113,990

343,383

1,073,990

408,600

Depreciation and amortization

356,597

802,796

713,421

1,605,668

Total operating expenses

7,527,258

6,006,128

13,713,017

38,047,137

Loss from operations

(7,345,054 )

(5,500,376 )

(13,360,592 )

(36,848,744 )

Other income/(expense):

Interest expense, net

(1,561,240 )

(1,184,040 )

(3,633,919 )

(2,278,530 )

Loss on extinguishment of vendor obligation

(320,000 )

(60,120 )

Loss on extinguishment of debt

(8,881,694 )

Loss on contract termination fee

(766,394 )

Settlement fees

(13,000 )

Other income

511,157

11,952

609,897

23,907

Total other expense, net

(11,018,171 )

(1,172,088 )

(12,745,230 )

(2,254,623 )

Net loss before income taxes

(18,363,225 )

(6,672,464 )

(26,105,822 )

(39,103,367 )

Provision for income taxes

Net loss

$ (18,363,225 )

$ (6,672,464 )

$ (26,105,822 )

$ (39,103,367 )

Weighted average common shares outstanding - basic and diluted

2,574,669

1,235,423

2,335,557

1,137,274

Net loss per common share - basic and diluted

$ (7.13 )

$ (5.40 )

$ (11.18 )

$ (34.38 )

###

-5-

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 7

v3.26.1

Cover

Aug. 17, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Aug. 17, 2026

Entity File Number

001-42530

Entity Registrant Name

DATAMEDS

AI, INC.

Entity Central Index Key

0002030763

Entity Tax Identification Number

93-3264234

Entity Incorporation, State or Country Code

Entity Address, Address Line One

3000

Bayport Drive

Entity Address, Address Line Two

Suite

950

Entity Address, City or Town

Tampa

Entity Address, State or Province

Entity Address, Postal Zip Code

33607

City Area Code

(844)

Local Phone Number

203-6092

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common Stock, $0.0001 par

value per share

Trading Symbol

MEDS

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

true

Elected Not To Use the Extended Transition Period

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 7A

-Section B

-Subsection 2

+ Details

Name:

dei_EntityExTransitionPeriod

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration